Stoke Therapeutics Inc (STOK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 184,420 | 36,555 | 8,780 | 12,405 | 0 |
| Gross Profit | 184,420 | 36,555 | 8,780 | 12,405 | N/A |
| Operating Expenses | 205,010 | 137,927 | 123,553 | 116,761 | 86,065 |
| Operating Income | -20,590 | -101,372 | -114,773 | -104,356 | -86,065 |
| Other Income | 13,705 | 12,391 | 10,074 | 3,289 | 260 |
| Pre-tax Income | -6,885 | -88,981 | -104,699 | -101,067 | -85,805 |
| Net Income Continuous | -6,885 | -88,981 | -104,699 | -101,067 | -85,805 |
| Net Income | $-6,885 | $-88,981 | $-104,699 | $-101,067 | $-85,805 |
| EPS Basic Total Ops | -0.12 | -1.65 | -2.38 | -2.60 | -2.34 |
| EPS Basic Continuous Ops | -0.12 | -1.65 | -2.38 | -2.60 | -2.34 |
| EPS Diluted Total Ops | -0.12 | -1.65 | -2.38 | -2.60 | -2.34 |
| EPS Diluted Continuous Ops | -0.12 | -1.65 | -2.38 | -2.60 | -2.34 |
| EPS Diluted Before Non-Recurring Items | -0.12 | -1.65 | -2.38 | -2.60 | -2.34 |
| EBITDA(a) | $-19,953 | $-100,837 | $-112,629 | $-103,021 | $-84,948 |